ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Long-Term Outcomes of Surgical Resection for Thymic Epithelial Tumour With Intrathoracic Dissemination.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe treatment of metastatic thymic epithelial tumours (TET) remains challenging with no established protocol, particularly regarding the feasibility of complete surgical resection. This study aimed to elucidate the long-term outcomes and identify risk factors influencing overall survival (OS) and progression-free survival (PFS) following surgical intervention.
methodsBetween July 2000 and November 2021, 149 patients underwent surgery for metastatic TET with intrathoracic metastases at a single centre. Of these patients, 121 met the inclusion criteria. Among them, 93 had thymoma including World Health Organization (WHO) types A, AB, and B1-B3, and 28 had thymic carcinoma. While 73 patients had pleural or pericardial seeding, 48 had lymph node or pulmonary metastasis. Synchronous metastasis was present in 72 patients, whereas 49 had metachronous metastasis.
resultsThe 5- and 10-year OS rates for the entire cohort were 76.4% and 55.1%, respectively. Multivariable analysis identified WHO type as a significant factor affecting OS (HR, 4.260; 95% CI, 2.139-8.482; P < .001). The 5- and 10-year PFS rates were 32.4% and 20.1%, respectively. In multivariable analysis, myasthenia gravis (MG) (HR, 0.362; 95% CI, 0.185-0.851; P = .018), WHO cell type (HR, 3.071; 95% CI, 1.857-5.079; P < .001), and number of metastases (HR, 2.396; 95% CI, 1.273-4.512; P = .007) emerged as risk factors for PFS.
conclusionsSurgical resection for metastatic TET with intrathoracic dissemination demonstrated favourable OS; however, high progression rates necessitated repeated treatments. Factors including the number of metastases, WHO cell type, and the presence of MG were identified as significant determinants influencing PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.